You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

CLINICAL TRIALS PROFILE FOR LENALIDOMIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for lenalidomide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed University of Wisconsin, Madison Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination NCT01245673 ↗ Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma Completed University of Pennsylvania Phase 2 2011-05-10 One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments is able to control the myeloma.
New Combination NCT01755975 ↗ Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Active, not recruiting Biologics, Inc. Phase 1/Phase 2 2012-12-01 The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.
New Combination NCT01755975 ↗ Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Active, not recruiting Celgene Corporation Phase 1/Phase 2 2012-12-01 The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.
New Combination NCT01755975 ↗ Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Active, not recruiting Saint Francis/Mount Sinai Regional Cancer Center Phase 1/Phase 2 2012-12-01 The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for lenalidomide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00031941 ↗ CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy Completed National Cancer Institute (NCI) Phase 1 2002-04-01 RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
NCT00031941 ↗ CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy Completed National Institutes of Health Clinical Center (CC) Phase 1 2002-04-01 RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
NCT00036894 ↗ CC-5013 in Treating Patients With Recurrent Glioma Completed National Cancer Institute (NCI) Phase 1 2002-03-01 RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
NCT00046735 ↗ Phase 1 Study OF CDC-501 in Patients With Solid Tumors Completed Celgene Phase 1 2002-06-01 To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.
NCT00046735 ↗ Phase 1 Study OF CDC-501 in Patients With Solid Tumors Completed Celgene Corporation Phase 1 2002-06-01 To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.
NCT00056160 ↗ CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Phase 3 2003-01-01 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for lenalidomide

Condition Name

Condition Name for lenalidomide
Intervention Trials
Multiple Myeloma 377
Chronic Lymphocytic Leukemia 45
Lymphoma 40
Plasma Cell Myeloma 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for lenalidomide
Intervention Trials
Multiple Myeloma 545
Neoplasms, Plasma Cell 527
Lymphoma 296
Leukemia 126
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for lenalidomide

Trials by Country

Trials by Country for lenalidomide
Location Trials
Belgium 88
Poland 68
Austria 67
Korea, Republic of 66
Netherlands 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for lenalidomide
Location Trials
New York 239
California 211
Texas 207
Ohio 165
Florida 164
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for lenalidomide

Clinical Trial Phase

Clinical Trial Phase for lenalidomide
Clinical Trial Phase Trials
Phase 4 21
Phase 3 147
Phase 2/Phase 3 10
[disabled in preview] 917
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for lenalidomide
Clinical Trial Phase Trials
Completed 377
Recruiting 236
Active, not recruiting 186
[disabled in preview] 287
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for lenalidomide

Sponsor Name

Sponsor Name for lenalidomide
Sponsor Trials
Celgene Corporation 270
National Cancer Institute (NCI) 179
Celgene 160
[disabled in preview] 143
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for lenalidomide
Sponsor Trials
Other 1261
Industry 941
NIH 191
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.